DS-5141 is a therapy being developed by the Japanese company Daiichi Sankyo for the treatment of Duchenne muscular dystrophy (DMD). The investigational drug received a Japanese SAKIGAKE designation in April 2017 that gives it priority for clinical trial consultation and review for the purpose of making the drug available to patients in Japan ahead of the rest of the world.
DS-5141 belongs to a group of treatments known as exon skipping treatments.
How does DS-5141 for DMD work?
DMD is characterized by the absence of dystrophin, a vital protein for correct muscle function. In DMD patients, the gene that carries the instructions for creating the dystrophin protein are altered, or mutated. When the cell’s reading machinery encounters the mutation, it immediately stops reading and, as a result, dystrophin is not formed.
DS-5141 works by binding to the mutation site, which makes the cell’s reading machinery skip the error and continue reading the gene farther ahead. The protein that is formed is incomplete since it lacks the portion of the information the drug is linked to, but a functional form of dystrophin is still formed.
This gene therapy might help DMD patients improve muscular function by lessening the effects of the genetic mutation. DS-5141 probably won’t improve all the symptoms of the disease but will make the symptoms less severe.
Studies of DS-5141
A Phase 1/2 clinical trial to evaluate the safety, tolerability, effectiveness, pharmacokinetics (how the drug is processed in the body), and determine the dosage for future studies of DS-5141 is underway in Japan (NCT02667483).
DMD patients participating in the study are given subcutaneous (beneath the skin) injections of DS-5141 and are followed for up for 12 weeks to assess the occurrence of adverse events and the drug’s period of activity, as well as the maximum dosage.
Top-line results were announced in April 2018 and no serious adverse events were observed. Efficacy goals of the study were mixed with dystrophin protein only being observed in some of the participants but messenger RNA with exon 45 skipping was detected in all participants. The press release stated that Daiichi Sankyo will continue to develop DS-5141.
Despite releasing top-line results, the study still states that it is “active, not recruiting” on the US Clinical Trials website and was updated in April of 2019 with a study completion date of December 2019.
Last updated: Oct. 21, 2019
Muscular Dystrophy News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.